A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of NNZ-2566 in the Acute Treatment of Adolescents and Adults With Mild Traumatic Brain Injury (mTBI)
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
Price : $35 *
At a glance
- Drugs Trofinetide (Primary)
- Indications Concussion
- Focus Therapeutic Use
- Sponsors Neuren Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 27 Mar 2017 Status changed from suspended to discontinued.
- 09 May 2016 Status changed from recruiting to suspended as data from another study requires re-evaluation of study design.